S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000843628.63947.e4 |
| _version_ | 1797281769544744960 |
|---|---|
| author | C. Touzeau A. Krishnan P. Moreau A. Perrot S. Z. Usmani S. Manier M. Cavo C. Martinez-Chamorro A. Nooka T. Martin L. Karlin X. Leleu N. Bahlis B. Besemer L. Pei R. Verona S. Girgis C. Uhlar R. Kobos A. Garfall |
| author_facet | C. Touzeau A. Krishnan P. Moreau A. Perrot S. Z. Usmani S. Manier M. Cavo C. Martinez-Chamorro A. Nooka T. Martin L. Karlin X. Leleu N. Bahlis B. Besemer L. Pei R. Verona S. Girgis C. Uhlar R. Kobos A. Garfall |
| author_sort | C. Touzeau |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:02:13Z |
| format | Article |
| id | doaj.art-b6fc590648824afb8b2a703bc35c4227 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:02:13Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-b6fc590648824afb8b2a703bc35c42272024-03-03T03:19:20ZengWileyHemaSphere2572-92412022-06-016858610.1097/01.HS9.0000843628.63947.e4202206003-00085S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTSC. Touzeau0A. Krishnan1P. Moreau2A. Perrot3S. Z. Usmani4S. Manier5M. Cavo6C. Martinez-Chamorro7A. Nooka8T. Martin9L. Karlin10X. Leleu11N. Bahlis12B. Besemer13L. Pei14R. Verona15S. Girgis16C. Uhlar17R. Kobos18A. Garfall191 University Hospital Hôtel-Dieu, Nantes, France2 City of Hope Comprehensive Cancer Center, Duarte, United States of America1 University Hospital Hôtel-Dieu, Nantes, France3 Centre Hospitalier, Universitaire de Toulouse, Service d’Hematologie, Toulouse, France4 Levine Cancer Institute/Atrium Health, Charlotte, United States of America5 University of Lille, Lille, France6 IRCSS Aziena Ospedaliero-Universitaria di Bologna, Bologna University School of Medicine, Bologna, Italy7 University Hospital Quirónsalud, Pozuelo de Alarcón, Madrid, Spain8 Winship Cancer Institute, Emory University, Atlanta9 University of California, San Francisco, San Francisco, United States of America10 Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite11 Centre Hospitalier Universitaire de Poitiers, Poitiers, France12 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada13 University of Tuebingen, Tuebingen, Germany14 Janssen Research & Development, Raritan15 Janssen Research & Development, Spring House15 Janssen Research & Development, Spring House15 Janssen Research & Development, Spring House14 Janssen Research & Development, Raritan16 Abramson Cancer Center, Perelman School of Medicine, Philadelphia, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000843628.63947.e4 |
| spellingShingle | C. Touzeau A. Krishnan P. Moreau A. Perrot S. Z. Usmani S. Manier M. Cavo C. Martinez-Chamorro A. Nooka T. Martin L. Karlin X. Leleu N. Bahlis B. Besemer L. Pei R. Verona S. Girgis C. Uhlar R. Kobos A. Garfall S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS HemaSphere |
| title | S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS |
| title_full | S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS |
| title_fullStr | S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS |
| title_full_unstemmed | S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS |
| title_short | S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS |
| title_sort | s184 evaluating teclistamab in patients with relapsed refractory multiple myeloma following exposure to other b cell maturation antigen bcma targeted agents |
| url | http://journals.lww.com/10.1097/01.HS9.0000843628.63947.e4 |
| work_keys_str_mv | AT ctouzeau s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT akrishnan s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT pmoreau s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT aperrot s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT szusmani s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT smanier s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT mcavo s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT cmartinezchamorro s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT anooka s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT tmartin s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT lkarlin s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT xleleu s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT nbahlis s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT bbesemer s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT lpei s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT rverona s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT sgirgis s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT cuhlar s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT rkobos s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents AT agarfall s184evaluatingteclistamabinpatientswithrelapsedrefractorymultiplemyelomafollowingexposuretootherbcellmaturationantigenbcmatargetedagents |